403 related articles for article (PubMed ID: 28622770)
1. Intensity-modulated radiation therapy from 70Gy to 80Gy in prostate cancer: six- year outcomes and predictors of late toxicity.
Jolnerovski M; Salleron J; Beckendorf V; Peiffert D; Baumann AS; Bernier V; Huger S; Marchesi V; Chira C
Radiat Oncol; 2017 Jun; 12(1):99. PubMed ID: 28622770
[TBL] [Abstract][Full Text] [Related]
2. Comparative toxicity and dosimetric profile of whole-pelvis versus prostate bed-only intensity-modulated radiation therapy after prostatectomy.
Deville C; Vapiwala N; Hwang WT; Lin H; Ad VB; Tochner Z; Both S
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):1389-96. PubMed ID: 21664069
[TBL] [Abstract][Full Text] [Related]
3. Clinical toxicities and dosimetric parameters after whole-pelvis versus prostate-only intensity-modulated radiation therapy for prostate cancer.
Deville C; Both S; Hwang WT; Tochner Z; Vapiwala N
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):763-72. PubMed ID: 20171807
[TBL] [Abstract][Full Text] [Related]
4. Late toxicity after intensity-modulated radiation therapy for localized prostate cancer: an exploration of dose-volume histogram parameters to limit genitourinary and gastrointestinal toxicity.
Pederson AW; Fricano J; Correa D; Pelizzari CA; Liauw SL
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):235-41. PubMed ID: 21163587
[TBL] [Abstract][Full Text] [Related]
5. Hypofractionated concomitant intensity-modulated radiotherapy boost for high-risk prostate cancer: late toxicity.
Quon H; Cheung PC; Loblaw DA; Morton G; Pang G; Szumacher E; Danjoux C; Choo R; Thomas G; Kiss A; Mamedov A; Deabreu A
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):898-905. PubMed ID: 21237581
[TBL] [Abstract][Full Text] [Related]
6. Impact of changing rectal dose volume parameters over time on late rectal and urinary toxicity after high-dose intensity-modulated radiotherapy for prostate cancer: A 10-years single centre experience.
Fonteyne V; Sadeghi S; Ost P; Vanpachtenbeke F; Vuye P; Lumen N; De Meerleer G
Acta Oncol; 2015 Jun; 54(6):854-61. PubMed ID: 25387271
[TBL] [Abstract][Full Text] [Related]
7. Role of principal component analysis in predicting toxicity in prostate cancer patients treated with hypofractionated intensity-modulated radiation therapy.
Vesprini D; Sia M; Lockwood G; Moseley D; Rosewall T; Bayley A; Bristow R; Chung P; Ménard C; Milosevic M; Warde P; Catton C
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e415-21. PubMed ID: 21477939
[TBL] [Abstract][Full Text] [Related]
8. Hypofractionated intensity-modulated radiotherapy (70 gy at 2.5 Gy per fraction) for localized prostate cancer: long-term outcomes.
Kupelian PA; Thakkar VV; Khuntia D; Reddy CA; Klein EA; Mahadevan A
Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1463-8. PubMed ID: 16169683
[TBL] [Abstract][Full Text] [Related]
9. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer.
Zelefsky MJ; Levin EJ; Hunt M; Yamada Y; Shippy AM; Jackson A; Amols HI
Int J Radiat Oncol Biol Phys; 2008 Mar; 70(4):1124-9. PubMed ID: 18313526
[TBL] [Abstract][Full Text] [Related]
10. Dose escalation with external beam radiation therapy and high-dose-rate brachytherapy combined with long-term androgen deprivation therapy in high and very high risk prostate cancer: Comparison of two consecutive high-dose-rate schemes.
Olarte A; Cambeiro M; Moreno-Jiménez M; Arbea L; Pérez-Gracia JL; Gil-Bazo I; Pascual I; Aristu J; Martínez-Monge R
Brachytherapy; 2016; 15(2):127-35. PubMed ID: 26832677
[TBL] [Abstract][Full Text] [Related]
11. Toxicity assessment of pelvic intensity-modulated radiotherapy with hypofractionated simultaneous integrated boost to prostate for intermediate- and high-risk prostate cancer.
McCammon R; Rusthoven KE; Kavanagh B; Newell S; Newman F; Raben D
Int J Radiat Oncol Biol Phys; 2009 Oct; 75(2):413-20. PubMed ID: 19362783
[TBL] [Abstract][Full Text] [Related]
12. Improved clinical outcomes with high-dose image guided radiotherapy compared with non-IGRT for the treatment of clinically localized prostate cancer.
Zelefsky MJ; Kollmeier M; Cox B; Fidaleo A; Sperling D; Pei X; Carver B; Coleman J; Lovelock M; Hunt M
Int J Radiat Oncol Biol Phys; 2012 Sep; 84(1):125-9. PubMed ID: 22330997
[TBL] [Abstract][Full Text] [Related]
13. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer.
Zelefsky MJ; Fuks Z; Hunt M; Lee HJ; Lombardi D; Ling CC; Reuter VE; Venkatraman ES; Leibel SA
J Urol; 2001 Sep; 166(3):876-81. PubMed ID: 11490237
[TBL] [Abstract][Full Text] [Related]
14. Outcome and toxicity for patients treated with intensity modulated radiation therapy for localized prostate cancer.
Vora SA; Wong WW; Schild SE; Ezzell GA; Andrews PE; Ferrigni RG; Swanson SK
J Urol; 2013 Aug; 190(2):521-6. PubMed ID: 23415964
[TBL] [Abstract][Full Text] [Related]
15. Image Guided Hypofractionated Postprostatectomy Intensity Modulated Radiation Therapy for Prostate Cancer.
Lewis SL; Patel P; Song H; Freedland SJ; Bynum S; Oh D; Palta M; Yoo D; Oleson J; Salama JK
Int J Radiat Oncol Biol Phys; 2016 Mar; 94(3):605-11. PubMed ID: 26867889
[TBL] [Abstract][Full Text] [Related]
16. Reduced late urinary toxicity with high-dose intensity-modulated radiotherapy using intra-prostate fiducial markers for localized prostate cancer.
Zapatero A; Roch M; Büchser D; Castro P; Fernández-Banda L; Pozo G; Liñán O; Martin de Vidales C; Cruz-Conde A; García-Vicente F
Clin Transl Oncol; 2017 Sep; 19(9):1161-1167. PubMed ID: 28374321
[TBL] [Abstract][Full Text] [Related]
17. Long-term Tumor Control and Late Toxicity in Patients with Prostate Cancer Receiving Hypofractionated (2.2 Gy) Soft-tissue-matched Image-guided Intensity-modulated Radiotherapy.
Shimizu D; Yamazaki H; Nishimura T; Aibe N; Okabe H
Anticancer Res; 2017 Oct; 37(10):5829-5835. PubMed ID: 28982908
[TBL] [Abstract][Full Text] [Related]
18. Acute toxicity in high-risk prostate cancer patients treated with androgen suppression and hypofractionated intensity-modulated radiotherapy.
Pervez N; Small C; MacKenzie M; Yee D; Parliament M; Ghosh S; Mihai A; Amanie J; Murtha A; Field C; Murray D; Fallone G; Pearcey R
Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):57-64. PubMed ID: 19395192
[TBL] [Abstract][Full Text] [Related]
19. Improved toxicity profile following high-dose postprostatectomy salvage radiation therapy with intensity-modulated radiation therapy.
Goenka A; Magsanoc JM; Pei X; Schechter M; Kollmeier M; Cox B; Scardino PT; Eastham JA; Zelefsky MJ
Eur Urol; 2011 Dec; 60(6):1142-8. PubMed ID: 21855208
[TBL] [Abstract][Full Text] [Related]
20. Impact of image guidance on toxicity and tumour outcome in moderately hypofractionated external-beam radiotherapy for prostate cancer.
Jereczek-Fossa BA; Maucieri A; Marvaso G; Gandini S; Fodor C; Zerini D; Riva G; Alessandro O; Surgo A; Volpe S; Fanetti G; Arculeo S; Zerella MA; Parisi S; Maisonneuve P; Vavassori A; Cattani F; Cambria R; Garibaldi C; Starzyńska A; Musi G; De Cobelli O; Ferro M; Nolè F; Ciardo D; Orecchia R
Med Oncol; 2018 Nov; 36(1):9. PubMed ID: 30483899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]